Sonova Holding AG

LSE:0QPY Stock Report

Market Cap: CHF 18.1b

Sonova Holding Valuation

Is 0QPY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QPY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QPY (CHF304.73) is trading below our estimate of fair value (CHF429.44)

Significantly Below Fair Value: 0QPY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QPY?

Key metric: As 0QPY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QPY. This is calculated by dividing 0QPY's market cap by their current earnings.
What is 0QPY's PE Ratio?
PE Ratio32.1x
EarningsCHF 564.70m
Market CapCHF 18.12b

Price to Earnings Ratio vs Peers

How does 0QPY's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QPY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31x
SN. Smith & Nephew
36.1x22.5%UK£8.7b
NIOX NIOX Group
22.9x15.8%UK£252.3m
CTEC ConvaTec Group
40.4x20.4%UK£4.9b
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
0QPY Sonova Holding
32.1x11.2%CHF 18.1b

Price-To-Earnings vs Peers: 0QPY is expensive based on its Price-To-Earnings Ratio (32.1x) compared to the peer average (31x).

Price to Earnings Ratio vs Industry

How does 0QPY's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QPY 32.1xIndustry Avg. 29.8xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QPY is expensive based on its Price-To-Earnings Ratio (32.1x) compared to the European Medical Equipment industry average (29.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0QPY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QPY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.1x
Fair PE Ratio39x

Price-To-Earnings vs Fair Ratio: 0QPY is good value based on its Price-To-Earnings Ratio (32.1x) compared to the estimated Fair Price-To-Earnings Ratio (39x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QPY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 304.73
CHF 296.28
-2.8%
14.1%CHF 375.00CHF 224.00n/a18
Nov ’25CHF 316.60
CHF 292.78
-7.5%
12.4%CHF 350.00CHF 227.00n/a18
Oct ’25CHF 301.65
CHF 287.53
-4.7%
11.3%CHF 345.00CHF 227.00n/a17
Sep ’25CHF 295.67
CHF 286.06
-3.3%
11.0%CHF 335.00CHF 227.00n/a17
Aug ’25CHF 266.50
CHF 284.82
+6.9%
11.8%CHF 335.00CHF 220.00n/a17
Jul ’25CHF 279.95
CHF 284.82
+1.7%
11.8%CHF 335.00CHF 220.00n/a17
Jun ’25CHF 283.46
CHF 279.12
-1.5%
12.6%CHF 335.00CHF 220.00n/a17
May ’25CHF 255.40
CHF 270.29
+5.8%
11.4%CHF 325.00CHF 200.00n/a17
Apr ’25CHF 261.14
CHF 270.65
+3.6%
12.0%CHF 325.00CHF 200.00n/a17
Mar ’25CHF 276.15
CHF 270.59
-2.0%
13.4%CHF 325.00CHF 200.00n/a17
Feb ’25CHF 279.07
CHF 267.06
-4.3%
14.7%CHF 325.00CHF 200.00n/a16
Jan ’25CHF 273.42
CHF 257.07
-6.0%
12.7%CHF 320.00CHF 200.00n/a15
Dec ’24CHF 255.23
CHF 259.75
+1.8%
13.4%CHF 340.00CHF 200.00n/a16
Nov ’24CHF 217.35
CHF 249.50
+14.8%
15.8%CHF 340.00CHF 195.00CHF 316.6016
Oct ’24CHF 216.90
CHF 252.81
+16.6%
16.3%CHF 340.00CHF 195.00CHF 301.6516
Sep ’24CHF 229.25
CHF 253.59
+10.6%
15.4%CHF 331.00CHF 195.00CHF 295.6717
Aug ’24CHF 242.32
CHF 253.59
+4.6%
15.4%CHF 331.00CHF 195.00CHF 266.5017
Jul ’24CHF 238.60
CHF 254.76
+6.8%
14.8%CHF 331.00CHF 195.00CHF 279.9517
Jun ’24CHF 235.88
CHF 248.91
+5.5%
14.6%CHF 320.00CHF 180.30CHF 283.4618
May ’24CHF 281.50
CHF 257.58
-8.5%
15.1%CHF 330.00CHF 180.30CHF 255.4016
Apr ’24CHF 268.57
CHF 257.33
-4.2%
15.2%CHF 330.00CHF 180.30CHF 261.1416
Mar ’24CHF 231.40
CHF 258.71
+11.8%
15.4%CHF 330.00CHF 180.30CHF 276.1516
Feb ’24CHF 232.25
CHF 258.71
+11.4%
15.4%CHF 330.00CHF 180.30CHF 279.0716
Jan ’24CHF 219.40
CHF 286.21
+30.4%
20.7%CHF 450.00CHF 180.30CHF 273.4216
Dec ’23CHF 247.38
CHF 291.29
+17.7%
20.0%CHF 450.00CHF 180.30CHF 255.2315
Nov ’23CHF 236.10
CHF 305.21
+29.3%
16.9%CHF 450.00CHF 255.00CHF 217.3514

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$403.49

7D

0.4%

1Y

-15.5%

Kooth

UK£64.8m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.78

7D

7.6%

1Y

-40.4%

Enovis

US$2.7b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$48.46

7D

9.7%

1Y

-3.3%